MAPT and Alzheimer disease: CSF biomarker studies that rely on decreased CSF Aβ42 levels to identify brain amyloid sequestration and mark the onset of preclinical AD [23] will have missed an earlier stage of elevated Aβ42 also accompanied by elevated tau levels.